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MicroRNAs (miRNAs) are small non-coding RNAs that inhibit gene expression at
transcriptional or post-transcriptional level. Let-7 family is among the first
identified human miRNAs and regulates multiple cellular processes including
glucose metabolism in multiple organs. It has been reported that overexpression
of let-7 resulted in insulin resistance and impaired glucose tolerance through
repressing insulin signaling pathway in both muscle and liver. However, the role
and mechanism underlying let-7 function in pancreatic beta-cells have yet to be
elucidated.
Let-7 family contains nine members, which poses a significant challenge in
complete deletion of this miRNA family. To study the function of let-7 and to
overcome the functional redundancies of various let-7 members in pancreatic
beta-cells, the highly expressed let-7a and let-7b were blocked simultaneously
using short tandem target mimic (STTM) approach developed in our laboratory.
Introducing STTM-let7 into beta-cells markedly increased the expression of
Caspase 3, a direct target of let-7, confirming a sufficient functional knockdown of
let-7a/b by STTM-let7. STTM-let7 enhanced apoptotic cell death induced by
cytokine, indicating that let-7a/b is able to protect from apoptosis through
attenuating Caspase 3 expression in pancreatic beta-cells. In contrast to the
previous observation that let-7 silencing increases insulin signaling in muscle and
liver, inhibition of let-7 with STTM-let7 significantly repressed glucose-stimulated
insulin signaling in pancreatic beta-cells, leading to impaired insulin secretion and
reduced beta-cell proliferation. Taken together, an appropriate level of let-7 is
essential in maintaining beta-cell function and viability. Dysregulation of let-7 may
contribute to the pathogenesis of type2 diabetes.
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1. Introduction
1.1 Diabetes and pancreatic beta-cells
Diabetes is a disorder of metabolism in which a person has high blood glucose
level (hyperglycemia). If left untreated, hyperglycemia can cause serious
complications, such as heart diseases and kidney failure(1). Diabetes is due to
either insufficient amount of insulin or dysfunction of insulin effects on the body.
There are three types of diabetes: type 1 diabetes, type 2 diabetes and
gestational diabetes. Type 1 diabetes (T1D) is characterized by loss of insulinproducing pancreatic 1-cell caused by autoimmune attack on the 1-cells. Type 1
diabetes is usually diagnosed in children and young adults and previously called
juvenile diabetes or "insulin-dependent diabetes"(2). Type 2 Diabetes (T2D)
results from the combination of resistance to insulin action in muscle and
adipocytes and insufficient insulin production 1-cells. Approximately90% of
diabetic patients are type 2 diabetes(3). Gestational diabetes is a type of
diabetes that only occurs during pregnancy in females who previously did not
have diabetes.
Type 2 Diabetes is one of the most prevalent diseases around the world. There
were approximately 285 million people diagnosed with T2D in 2010(4).
Development of type 2 diabetes involves multiple metabolic defects, mainly due
to insulin resistance and 1-cell dysfunction. Most people with insulin resistance
fail to respond to normal circulating insulin, causing reduced glucose uptake in
muscle and fat tissues, increased glucose production and release in liver, which
all in turn result in elevated blood glucose levels(5).If insulin resistance exists,
much higher insulin requires to be secreted to blood from pancreatic 1-cells, a
condition called hyperinsulinemia(6). Hyperglycemia combined with
hyperinsulinemia generate various toxicities, such as free fatty acids, reactive
oxygen species and inflammatory cytokines, which result in 1-cell dysfunction
including reduced insulin secretion and insulin biosynthesis, increased 1-cell
death and eventually loss of 1-cell mass(7-9).
Pancreatic 1-cells are the only source for producing insulin and insulin is the key
hormone responsible for maintaining glucose homeostasis. In 1-cell, insulin
1

biosynthesis and release are tightly regulated by insulin signaling pathway that
maintain the 1-cell fate and activate specific transcription factors in response to
the change of plasma glucose(10). The insulin signaling pathway involvesinsulin
activated insulin receptor (IR), insulin receptor substrate (IRS1/2),
phosphorylation, and activation of phosphatidylinositol 3-kinase (PI3-K), Akt (also
known as protein kinase B), and mammalian target of rapamycin (mTOR)(Figure
1.1)(10).Studies in diabetic animal models and humans have consistently
demonstrated that dysregulation of insulin signaling is associated with impaired
insulin secretion and insulin biosynthesis. Overexpression of insulin receptor in 1cells was found to promote insulin transcription and regulate the steady-state
insulin content (11). Leibiger and his colleagues reported type A insulin receptor
controlled insulin gene transcription whereas stimulation of type B insulin
receptor promoted 1-cell glucokinase gene expression (12). Insulin receptor
substrate 2 (IRS-2) branch of the insulin/insulin-like growth factor signaling is
capable of mediating pancreatic 1-cell proliferation and function. Exendin-4
promoted IRS-2 expression and Akt phosphorylation were able to delay
progression of diabetes and to stimulate insulin secretion (13). IRS-2 was also
shown to be regulated by negative feedback effects of mammalian target of
rapamycin (mTOR). Chronic activation of mTOR resulted in degradation of IRS-2
followed by deactivation of Akt/PKB and elevation of 1-cell apoptosis.(14) This
work provided another mechanism indicating why 1-cell is damaged by chronic
hyperglycemia in the development of type 2 diabetes.
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Figure 1.1 Glucose and insulin stimulated insulin signaling pathways in
pancreatic 1-cells. Insulin molecules interact with Insulin receptor (IR) and
activate both the mitogenic (via MAP kinase) and metabolic branches involving
phosphoinositide 3 (PI3)-kinase, protein kinase B (PKB, also called Akt),
mammalian target of rapamycin (mTOR). Adapted from (10).
The development of type 2 diabetes is associated with a loss of 1-cell mass. The
1-cell mass is maintained by the dynamic balance of proliferation and cell death.
Under normal conditions, the proliferation and apoptosis rate are very low(15).
However, in the late phase of diabetes, 1-cell mass is significantly decreasing
due to an enhanced 1-cell apoptosis. Evidences have demonstrated the
proinflammatory cytokines stimulate 1-cell apoptosis by activating Bcl-2 regulated
intrinsic apoptotic pathway(16)(Figure 1.2). The proapoptotic members, Bax and
Bak, directly promote mitochondrial swelling and release of cytochrome C.
Cytochrome C release leads to the formation of an apoptosome, which in turn
activates caspase-3 and ultimately induces cell apoptosis(17,18). Antiapoptotic
Bcl-2 family sequesters Bax and Bak in the cytosol, thus inhibiting apoptosis.
Understanding how cytokine triggers 1-cell apoptosis is likely to shed new light
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on mechanisms of 1-cell loss in diabetes and may therefore find the way to
improve therapeutic intervention.

Figure 1.2 Diagram of cell death signaling. Cell death can be initiated through
intrinsic pathway (Mitochondria) or extrinsic pathway (ligand-receptor binding).Both
of them require the activation of initiator caspases (CASP8, CASP9)
and effector caspases (CASP3). Let-7 was revealed to suppress the expression
of Caspase-3 (19). Bax and Bcl-2 are antagonistic regulators mediate the release
of Cytochrome C from mitochondria.
1.2 Role of microRNA in beta cells
MicroRNA (miRNA) is a small (-22 nucleotides) non-coding RNA located in the
introns or non-coding region of genome. MiRNAs can be found in plants, animals
and some virus, in which they regulate gene expression on transcriptional or
post-transcriptional level. Containing the complementary sequences to the
messenger RNA (mRNA), miRNAs interact with their target mRNA through base
pairing, resulting in inhibition or degradation of the mRNA(20). In human body,
miRNAs mainly repress translation by binding imperfectly with 3'-untranslated
region of their targets. Generally, one single miRNA regulates expression of
multiple genes and one single mRNA is controlled by a combination of multiple
4

miRNAs(20,21).In animal cells, the biogenesis of miRNAs starts from transcribing
miRNA genes to primary transcripts (pri-miRNAs) by RNA polymerase II (Pol II).
The poly-A tail of pri-miRNA is cropped by the Drosh complex, generating the
precursor miRNA (pre-miRNA) which has a hairpin structure with a -2-nucleotide
3' overhang. Pre-miRNA is recognized by exportin-5 and transported into
cytoplasm in which the pre-miRNA is cleaved by Dicer to produce miRNA duplex.
Dicer and Argonaute (AGO2)(22) mediate the processing of pre-miRNA and
assemble the RNA-induced silencing complex (RISC). One strand of the miRNA
is degraded whereas the other is incorporated into AGO protein as the mature
miRNA. AGO2 is responsible for possessing the inhibition of target mRNA(23,24)
(Figure 1.3).

Figure 1.3 Diagram of miRNA biogenesis in animals. miRNAs are first
transcribed into pri-miRNA and undergone the processing of Drosha. After
exportation out of nucleus, Dicer, TAR RNA-binding protein (TARBP2), protein
activator of the interferon induced protein kinase (PACT) and Argonaute (AGO2)
5

(22) mediate the cleavage of pre-miRNA and are assembled to RNA-induced
silencing complex (RISC). Adapted from (24).
MicroRNAs play diverse roles in many biological processes, including
proliferation, differentiation and apoptosis. Dysregulations of miRNAs thus are
involved in various diseases like cancer and diabetes. Several miRNAs have
been identified as pathological factors contribute to the development of
diabetes(25).Previously, miR-375 was found to be elevated in patients with type
2 diabetes. Overexpression of miR-375 results in reduced expression of
mytrophin (MTPN) and t-SNAREs yeast homologue 1A (Vtila), leading to
impairment of insulin secretion(26,27).MiR-375 was further found to be required
for maintain 1-cell mass. Genetic deletion of miR-375 impairs the proliferation of
pancreas and results in a severely diabetic state, whereas the miR-375 knockout
mice have increased pancreatic alpha cell mass and glucagon levels(28). miR30d was shown to associate with the expression of MafA, an insulin gene
transcription factors as well as prevent the reduction of IRS-2 from tumor
necrosis factor alpha(TNF-a) exposure(29).MiR-29a/b/c was increased in isolated
islets of prediabetic non-obese diabetic (30) mice with impaired insulin
secretion(31). Other miRNAs regulating pancreatic 1-cell function include miR144 that was upregulated in blood, pancreas, liver and skeletal muscles of type 2
diabetes model rats (32,33)and miR-24 that overpression inhibited insulin
secretion and 1-cell proliferation by targeting two maturity onset diabetes of youth
(MODY) genes (34).
1.3 Let-7 family of microRNAs
In this study, we identified the specific functions of a highly conserved miRNA
family, let-7, in pancreatic 1-cells. Let-7family of miRNAs is one of the most
abundant miRNAs expressed among animals. In mice, there are nine differentlet7 members encoded by 12 genes in which let-7a has identical sequence across
various species from C. elegans to human. All of let-7 family members are
believed to have similar functions because of the same seed sequences in their
mature form(35,36). Let-7 family was first identified as tumor suppressor by
negatively regulating many oncogenes. In human cancers, loss of let-7 was
6

discovered resulting in upregulation of some cell-cycle factors, including RAS,
MYC, HMGA2 (high mobility group AT-hook 2), cyclin D and CDC34. Increasing
of these let-7-targeted genes leads to dysfunction of cell growth and proliferation
and termination of normal differentiation and the emergence of malignancy(3739). Interestingly, let-7a was nevertheless found to suppress cytokine-induced
cancer cell death by inhibiting the expression of caspase-3, an executioner
caspase that initiate apoptosis (19) (Figure 1.2). Let-7 family also regulated
glucose metabolism in multiple organ through lin28/let-7 axis. Lin28 and let-7
were mutually antagonistic regulators involved in glucose homeostasis. Lin28
transgenic mice were resistant to obesity and diabetes and exhibited enhanced
glucose tolerance. Hao Zhu and his colleagues reported that proteins associated
with insulin signaling, such as IRS-2, IGF1R (insulin-like growth factor 1receptor),
PIK3IP1 (phosphoinositide-3-kinase interacting protein 1), Akt2 and EIF4EBP2
(eukaryotic translation initiation factor 4E-binding protein 2) were all predicted to
contain let-7 binding sites(30). Further study indicated transgenic mice globally
overexpress let-7 exhibited glucose intolerance and reduced glucose-stimulated
insulin secretion. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT)
in transgenic mice suggested insulin resistance in peripheral tissues and the
reduction of glucose tolerance was caused solely by insufficient insulin. Knock
down of let-7 was sufficient to lead to increased insulin secretion and recovery of
insulin sensitivity(36). Although being comprehensive and insightful, previous
studies do not provide the information onlet-7in specific tissues and the function
of let-7 in pancreatic 1-cells is incomplete and remains to be determined.
1.4Methods to silence/block miRNA family function
miRNAs generally exist as multiple family members and display significant
functional redundancy. Therefore, it is important to silence specific miRNA and
reveal its biological function and its underlying regulatory networks. Currently,
there are three approaches used for loss of miRNA function: genetic knockouts,
miRNA sponges and antisense oligonucleotides(40). The traditional methods for
gene functions by gene knockout are not very effective in studies of miRNA
because of the small sizes and multiplicity of miRNA genes distributed over the
7

intergenic regions(41). miRNA sponges are transgenes that express in cells and
generate the transcripts containing multiple miRNA binding sites. The promoterdriven sponges are allowed to contain a fluorescence reporter gene for
identification and selection(42). Another approach in miRNA loss-of-function
studies is to introduce chemically synthesized antisense oligucleotides, or
antimiRs. The antimiRs are presumed to anneal to and block the mature miRNA
through sequence complementarities(43).
In this study, we construct the short tandem target mimic (STTM) to block the
functions of miRNA. STTM is a powerful technology complementary to miRNA
sponges. STTM is an artificial non-coding RNA consists of two miRNA binding
sites and a spacer linker(Figure 1.4).The binding sites for a miRNA are perfectly
complementary to their targets with a bulge at the central three nucleotides in
order to prevent miRNA mediated cleavage and degradation. The spacer is 4888 nucleotides long with a weak hairpin secondary structure (41,44).
Effectiveness of STTM has been confirmed by STTM-165/166 in plant (45) and
STTM-30 in pancreatic 1-cells (44).

Figure 1.4 Structure of STTM RNA transcripts. A 48-88 nt spacer with the
stem loop structure is flanked by two small RNA binding sites. The bulge
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introduced into binding sites stabilizes the interactions with miRNA and prevents
itself from being cleaved. Adapted from (44).
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2. Objective
In this study, the objective was to identify the biological functions of let-7
microRNA in pancreatic 1-cells by blocking expression of endogenous let-7 using
STTM methods. The hypothesis is that changes of let-7 in pancreatic 1-cells can
result in significant differences in cell proliferation, cell death as well as insulin
secretion of 1-cells. The mainly objective of this work is to examine the target
gene regulated by let-7 and investigate the molecular mechanisms underlying the
biological alterations.
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3. Materials and methods
Construction of STTM-let7
To block the expression of both let-7a and let-7b in pancreatic 1-cells, a STTM
sequence complementary to let-7a (AACTATACAACCctaTACTACCTCA) and
let-7b (AACCACACAACCctaTACTACCTC) with an 88 nt spacer in between
(total 138 bp) was synthesized and cloned into the pEGP-miR vector as
described (44) (Figure 3.1).

Figure 3.1 Schematic representations of pEGP-miR cloning and expression
vector for STTM-let7a/b and pEGP-miR Null control vector. (A) pEGP-miR
(4972bp). The two sites for cloning of STTM in Human 1-globin intron are BamHI
and NheI. Positions indicating EF-1a promoter, GFP-Puro fusion protein, SV40
Polyadenylation signal and the human 1-globin intron are shown in the diagram.
(B) pEGP-miR Null (4.7kb). The pEGP-miR Null control vector cannot be
digested with BamHI due to secondary structure. (C) The sequences of STTMlet7a/b cloned into pEGP-miR vector. Two restriction enzyme recognition sites
(BamHI and NheI) are shown.
Cell culture and transfection
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The pancreatic 1-cell line MIN6 was cultured in DMEM/high glucose (Thermo
Scientific, Waltham, MA) with 15% fetal bovine serum (FBS) (Atlanta biologicals,
Flowery Branch, GA), 100U/ml penicillin and 100 U/ml streptomycin. Cells were
maintained in a 5% CO2 humidified atmosphere incubator (Thermo Scientific,
Waltham, MA) at 37 C. The culture medium was replaced every 48h. For
transfection, MIN6 cells were trypsinized and pelleted at 700 rpm for 3 min. Cell
pellets were resuspended in 100 µl Nucleofector buffer (4D Nucleofector X kit L)
(Lonza, Basel, Switzerland). 10 µg of plasmids for pEGP-STTM-let7 and pEGPNull control vector were used for transfection according to the protocol. 3 days
after transfection, MIN6 cells were treated with cytokines mix (10ng/ml, IL-11,
IFN-y and TNF-a) for 12-24h.
Isolation of pancreatic islets and virus infection
Islets were isolated from 10- to 16-week wild type mouse using collagenase
digestion and cultured in RPMI medium. After incubating for 24h, islets were
infected with recombinant adenovirus as previously described (46)and plated in
60 mm Petri-dish. Islets were collected 2 days after infection and perform
western blot as described below.
Luciferase reporter assay
To evaluate the silencing efficiency of STTM-let7, let-7a complementary
sequence or mutant was subcloned into the pRLTK vector (Promega, Madison,
WI). For the luciferase reporter assay, pRLTK reporter constructs (2 µg) were
electorporated into MIN6 cells (106) with pEGP-STTM-let7 or pEGP-Null control
vector using Amaxa (Lonza). The plasmid PGL-3 containing firefly luciferase (2µg)
was co-transfected together to normalize for transfection efficiency. Luciferase
activity was measured with a dual-luciferase reporter assay kit (Promega) two
days after transfection.
RNA isolation and real-time PCR
Total RNA from MIN6 or islets was extracted using Trizol reagent (Roche, Basel,
Switzerland) or miRNasy Mini Kit (QIAGEN, Venlo, Netherlands) and reversetranscribed using TaqMan MicroRNA Reverse Transcription Kit (Applied
12

Biosystems, Carlsbad, CA). Quantitative RT-PCR was performed using the
SYBR Green Master Mix and StepOnePlus Real-Time PCR System (Applied
Biosystem). miRNA levels were normalized by the relative expression of U6.
Western blot analysis
MIN6 cells were cultured and treated as described above and lysed with lysis
buffer containing 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.2%
SDS, phosphatase inhibitor and proteinase inhibitor (1 ml, Sigma, St. Louis, MO).
Protein concentration was determined using PierceBCA Protein Assay Kit
(Thermo Scientific) and 150µgtotal protein samples were separated by SDSPAGE. Immunoblotting was performed with antibodies purchased from Cell
Signaling (Beverly, MA) diluted according to the protocols.
Cell proliferation assay
DNA synthesis was measured using cell proliferation ELISA kit (Roche). MIN6
cells were transfected as described. At 48h after transfection, cells were
collected and seeded in a 96-well plate to the density of 4x104 per well. BrdU
were added to culture medium to a final concentration of 10µM. After BrdU
labeling for 12-24h, the cells were processed according to the protocol.
Cell Apoptosis
At 48h after transfection, cells were collected and seeded in a 96-well plate. After
incubating in the plate for 24h, cytokines mix was added to culture medium to the
final concentration of 10ng/ml. According to the cell death detection ELISA
(Roche) kit, anti-histone biotin and anti-DNA-POD were added to each well to
measure the levels of cell death.
Glucose Stimulated Insulin secretion
As described above, MIN6 cells were seeded in 35 mm dish and incubated for 3
days followed by 12-24h treatment of cytokines mix. Afterwards, cells were preincubated for 2h in Krebs-Ringer bicarbonate HEPES buffer (KRB) and then
cultured in KRB containing 25mM glucose for 1h. After the incubation period,
supernatants were collected for stimulated insulin secretion and cell pellets were
13

processed for total insulin content. Insulin levels were measured using Mouse
Insulin ELISA Kit (Mercodia, Uppsala, Sweden) and normalized to DNA
concentration of the cell pellets.
Statistical analysis
For comparisons, statistical significance was evaluated using a two-tailed
Student t test. A p value of less than 0.05 was considered significant.
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4. Results
4.1 STTM-let7 reduces expression of let-7 in 1-cells
The STTM-let7a/b constructed was synthesized and ligated with pEGP-miR
vector that digested using BamHI and NheI as described above. To investigate
the expression of STTM-let7 and inhibition of endogenous let-7, pEPG-Null
control vector and pEGP-STTM-let7 were transfected into MIN6 cells respectively.
Cells were collected for Northern blot to detect the expression level of let-7a.
Endogenous let-7a was down-regulated in cells transfected withSTTM-let7
compared with control group(Figure 4.1 A).In order to further determine the
silencing efficiency of STTM-let7, let-7a or mutant let-7 recognition sites were
cloned into 3'UTR of pRLTK luciferase vector and luciferase reporter assays
were performed. Co-transfection with STTM-let7was capable of decreasing
luciferase activity of the wild type constructs, whereas the reporter with mutant
let-7 sites was not affected (Figure 4.1 B).

Figure 4.1 STTM-let7 reduces the expression of let-7. A: Northern blot
analysis of total RNA from MIN6 cells transfected with pEGP-STTM-let7 or
pEGP-Null control vectors with 32P-labeled let-7a probe (left). Let-7 level was
normalized to U6 as fold change(right). B: the pRLTK-let7 luciferase reporter
construct was co-transfected into MIN6 cells along with pEGP-STTM-let7 or
pEGP-Null control, respectively. The luciferase activities were normalized by the
co-transfected pGL3 firefly luciferase activity.**, P<0.01
4.2 Let-7 suppress cell death by targeting caspase-3
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To understand the biological effects caused by the decrease of let-7 in 1-cells,
we examined the expression level of let-7 targets by western blot. As expected,
expression of caspase-3, which was reported to be one oflet-7 targets(19), was
elevated when endogenous let-7 was inhibited by STTM (Figure 4.2 A, B) in
MIN6 cells and islets. Caspase-3 belongs to the group of effector caspase family,
which are located downstream of cell death pathway and can be activated
through intrinsic pathway (Mitochondria) or extrinsic pathway (ligand-receptor
binding)(17). Activation of Caspase-3 requires proteolytic cleavage of itself into
17kDa and 12kDa subunits. The intrinsic apoptotic pathway is mainly mediated
by Bcl-2 family members that center at mitochondria. Bax and Bcl-2, two
antagonistic Bcl-2 family proteins regulating apoptosis, were all increased by
STTM-let7independent of cytokines induced extrinsic cell death pathway. The
elevation of Bcl-2 family by inhibition of let-7 suggested let-7 might play critical
roles on regulating cell death.
The effect of let-7 on cell death was confirmed through cell death assay in MIN6
cells. In the presence of cytokines treatment, inhibition of let-7 by introducing
STTM-let7 significantly increased cell death, which was correlated to the
increased Caspase-3 expression (Figure 4.2 C). Under normal growth conditions,
MIN6 cells displayed a low level of cell death rate and inhibition of let-7 had no
effect.

16

Figure 4.2 Inhibition of let-7 by STTM-let7 induces cell death by targeting
caspase-3. A: STTM-let7 increased the expression of caspase-3 and Bax. MIN6
cells were transfected with STTM-let7 or control vector, After 48 h, cells were
treated with cytokine (10 g/ml) for 16 h and the expression of caspase-3,
cleaved caspase-3, Bcl-2 and Bax were measured by Western blot. B: STTM-let7
increased the expression of caspase-3 and Bax in isolated islets infected with
AD-STTM-let7 virus. C: STTM-let-7 Increased cytokine-induced cell death in
MIN6 cells. *, P<0.05.
4.3 Let-7 promotes 1-cell proliferation
To assess the contribution of let-7 to cell proliferation, BrdU incorporation was
performed in MIN6 cells after transfection. After incubating for 24h, STTM-let7
was capable of decreasing BrdU signal and inhibiting cell proliferation (Figure 4.3
A).For the cells treated with cytokines, there was no difference in BrdU signal
because of the intensive cell death rate. Western blot analysis indicated that IRS17

2 and mTOR, two factors involved in insulin signaling and regulate 1-cell function,
were both down-regulated by STTM-let7 (Figure 4.3 B). However, the expression
of Akt and phosphor-Akt was not changed significantly. Akt2 was predicted
containing the miRNA recognition sites of let-7 and it was phosphorylated by
mTOR complex 2 (mTORC2) at Serine 473 (47). Activation of Akt2 subsequently
phosphorylates mTOR at Serine 2448 and results in activation of mTOR complex
1 (mTORC1). On the other hand, one of the insulin transcription factors, MafA,
was not affected by STTM-let7 as expected for the reason of lacking let-7
recognition sites. However, STTM-let7 had no significant effects on the
expression of mTOR, IRS-2 and Akt in islets with AD-STTM-let7 (data not
shown).

Figure 4.3 Inhibition of let-7 by STTM-let7 inhibit 1-cell proliferation by
down-regulating insulin signaling. A: MIN6 cells were transfected with STTMlet7 or control vector. After 48 h, cell proliferation was measure by BrdU
incorporation after incubated with cytokine (10 g/ml) for 16 h. B: Western blot
validated that STTM-let7 decreased the expression of IRS-2, p-Akt, p-mTOR and
mTOR. The expression of MafA had no significant effect.
4.4 Let-7 positively regulates glucose-stimulated insulin secretion
Glucose stimulated insulin secretion assay of MIN6 cells was performed to
investigate the effects of let-7 on 1-cell function. Increased glucose level is
18

capable of inducing insulin secretion by causing production of ATP and elevation
of cellular Ca2+, and finally leads to the release of synthesized insulin from
secretory vesicles. Consistent with the repressed insulin signaling,STTMlet7inhibited glucose-stimulated insulin secretion as well as total insulin
content(Figure 4.4 A, B). Given the previous studies about insulin exocytosis was
associated with insulin signaling (15), IRS-1 and PI3 kinase act as regulators
controlling intracellular Ca2+ released from endoplasmic reticulum. As a result,
the inhibition of insulin signaling in 1-cells also contributes to the reduction of
insulin secretion.

Figure 4.4 Inhibition of let-7 by STTM-let7 decreased insulin secretion in
pancreatic beta cells.MIN6 cells were transfected with STTM-let7 or control
vector. After 48 h, the secreted insulin in the medium (A) and insulin content (B)
were quantified using mouse insulin ELISA and normalized to total DNA. The
presented data are the average of three independent experiments S.D.
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5. Discussion
In this study, we observed that the expression of let-7 family was successfully
blocked by the newly developed STTM technology. Inhibition of let-7 by STTMlet7 reduced 1-cell proliferation and induced 1-cell death through Caspase-3
mediated apoptosis pathway. Moreover, reduced let-7 expression impaired
insulin signaling and decreased glucose-stimulated insulin secretion. Taken
together, let-7 promotes 1-cell proliferation and protects against cytokine-induced
apoptosis. Let-7 also plays a key role in regulating insulin secretion by activating
insulin signaling.
Although let-7 was revealed to regulate apoptotic cell death by negatively
regulating Caspase-3, whether other factors involved in cell death signaling are
affected is less known. In this study, we show that let-7 inhibits two factors
controlling initiation of cell death, Bax and Bcl-2. The elevation of Bax and Bcl-2
can be observed in MIN6 cells transfected with STTM-let7 with or without
cytokines treatments, indicating let-7 regulates cells death independent of
cytokine-induced extrinsic pathway. Cell death ELISA assay indicates that upregulation of Caspase-3 by STTM-let7 sufficiently lead to a significant increase in
cell death after cytokines inducement. Caspase-3 exists as an inactive form that
is triggered by extracellular or intracellular stimulations through activation of
initiator caspases (Caspase 8, 9 and 10) (17). Although increased Bax/Bcl-2 ratio
was observed associated with increased Caspase-3 and apoptosis (48), the
other caspases (caspase-8 or -9) downstream from Bax/Bcl-2 were not affected
in the studies where caspase-3 was inhibited by overexpression of let-7(19). It
could be the reason that Bax and Bcl-2 are up-regulated at the same extent and
Bax/Bcl-2 ratio remains the same without affecting the downstream cell signaling.
Whether let-7 inhibits the expression of Bax and Bcl-2 directly is unknown,
however, let-7plays a role in regulating the center of cell death, Caspase-3.
Based on previous reports that let-7 can regulate glucose metabolism through
Lin28/let-7 axis (30), let-7 controls glucose homeostasis and affects insulin
sensitivity in muscles and liver by suppressing insulin signaling pathways. Insulin
receptor (INSR), IRS-2, insulin-like growth factor 1 receptor (IGF1R), mTOR and
Akt2 were confirmed to be regulated by let-7 through luciferase reporter assay
(30,36). However, the previous studies primarily focused on insulin action on
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insulin-target tissues rather than insulin secretion. Here, let-7 was revealed to
promote insulin secretion and insulin signaling in 1-cells. IRS-2, which capable of
promoting 1-cell growth and function (13), could play critical roles in let-7
mediated activation of insulin signaling. Decreased insulin secretion observed in
cells transfected with STTM-let7 can be caused by inactivation of insulin
signaling or impaired cell proliferation. Frost and Olson (36) have reported the
decreased insulin secretion in let-7 globally knock-out mice. Theoretically, absent
of let-7 in pancreas should promote insulin signaling and result in enhanced 1cell function. However, a low level of insulin secretion in transgenic mice was
observed, suggesting the potential effects of let-7 on maintaining glucose
homeostasis. In our study, the inhibition of IRS-2 and mTOR in the presence of
STTM-let7 indicates the reversal of let-7 effects on the mRNA of these genes. In
contrast, the other let-7 target, Akt2 was not changed. The other isoform of Akt,
Akt1 was ever revealed to regulate cell cycle by regulating Cyclin D1 and cyclindependent kinase-4 (49). Both of Akt1 and Akt2 were activated through
mTORC2-mediated phosphorylation at Serine 473(47) although only Akt2 was
predicted to be regulated by let-7. Absence of the alteration in Akt and p-Akt
could be caused by the slight change of Akt expression and the antibody
targeting total Akt content. The unaffected phosphor-Akt also suggests
phosphorylation of Akt was not influenced by the decreased mTOR in mTOR
Complex 2. Although an intact mTOR Complex requires phosphorylation of
mTOR, recent data renders that mTOR is phosphorylated diversely when
associated with mTORC1 and mTORC2 (50). The specific phosphorylation of
mTOR in mTORC1 is primarily on Serine 2448 whereas mTOR in mTORC2 is
phosphorylated on Serine 2481. It is mTORC2 that phosphorylate Akt1 and Akt2
at Serine 473. mTORC1 locates downstream from Akt and is activated through
insulin signaling. Phospho-mTOR at Serine 2448 was detected and revealed to
be repressed because of STTM-let7 (Figure 4.3 B). Unaltered phosphor-Akt
provides the evidence that decrease of phosphor-mTOR only results from the low
expression of mTOR, regardless of the activation of phosphor-Akt. Indeed, Ser2448 phosphorylation of mTOR was reported to be regulated by p70S6 kinase
downstream from mTOR (51).
Other studies demonstrate that the effect of let-7a on target mRNA is reversed in
immune-stimulated cells (52) and translation of HMGA2 is activated by let-7 in
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the cells arrested in G0phase of cell cycle (53).Bhattacharyya, et al discovered
that he reversal of miRNA repression was mediated by mRNA processing bodies
(P bodies) in response to different stress conditions (54). However, it is not
confirmed whether the activation of insulin signaling by let-7 results from stressinduced reversal of mRNA repression. And in islets consist of alpha cells and 1cells, IRS-2 and mTOR wasn't changed significantly by STTM-let7, suggesting
let-7 may play different roles in different types of cell.
The decrease of insulin secretion caused by down-regulation of let-7 in MIN6
cells can be a combination of inhibited 1-cell growth and deactivation of insulin
signaling. Changes of total insulin content suggest the let-7 promotes insulin
expression by regulating cell proliferation. And essentially, insulin signaling also
influences the Ca2+level and directly affect the exocytosis of insulin vesicles (15).
As mentioned above, increase of Ca+ was revealed partially dependent on IRS-1
and PI3 kinase(55). Recent data also indicates various intracellular factors
involved in cell signaling contribute greatly to GSIS in compared with glucose
itself (56). From the previously studies regarding the effects of insulin molecules
on insulin secretion (15), it can be inferred there is a complex feedback
mechanism that helps 1-cells auto-regulate their functions through insulin
signaling.
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6. Future work
In this study, the effects of let-7 on pancreatic 1-cells were mainly focused on
MIN6 cell line. And the molecular mechanisms underlying the biological changes
were not fully understood. In future work, STTM-let7 can be used for repression
of let-7 in mice islets. Insulin promoter region will be used driving the expression
of STTM in the 1-cell of mouse pancreas. Whether let-7 regulates 1-cell function
can be determined in vivo by examining glucose metabolism in the transgenic
mice. Globally inhibition of let-7 in mouse had been shown associated with
increased insulin sensitivity and enhanced glucose tolerance (36). For the mouse
specifically inhibit let-7 in 1-cells, glucose tolerance tests (GTT) will be performed
to confirm the response of 1-cell to glucose stimulation.
The action of let-7 in other tissue cells should be examined for comparison with
let-7 in 1-cells. Insulin signaling pathways in different tissues may be responsible
for various functions and thus they are mediated in different manners. Another
strategy resolving the question is to silence one of the genes involved in insulin
signaling. Let-7 mediated 1-cell function could base on either a combination of
multiple let-7 target genes or a few critical genes. In addition, the activation time
of insulin signaling presumably leads to diverse effects on insulin secretion in
response to glucose (15).
Although well known as a tumor suppressor, let-7 was recently reported to
regulate cell death by targeting Fas (57) and Caspase-3 (19). Our work further
revealed let-7-mediated apoptosis was associated with Bax/Bcl-2 ratio in
mitochondria. It is essential to examine the miRNA involved cell death signaling
in other types of cell. Overexpression of let-7 in those cells will provide more
information about let-7 effects on cell growth and cell death.
Finally, 1-cell mass can be measured in isolated islets from the transgenic mice
specifically silence let-7 in pancreas. Considering the low proliferation rate and
apoptosis rate of 1-cells, whether absence of let-7 will result in a significant
difference is unknown. Since let-7 is responsible for regulating glucose
homeostasis and insulin sensitivity, dysfunction of let-7 in 1-cells may also
contribute to the development of type 2 diabetes.

7. Conclusion
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Short tandem target mimic (STTM) is capable of inhibiting the expression of
endogenous microRNA let-7 in pancreatic 1-cells. Let-7 miRNA family plays
significant roles on the normal function of 1-cells. Through STTM approach, let-7
was shown to protect 1-cells from cytokine induced cell death by suppressing
Bax-Caspase-3 apoptotic cascade. Moreover, for the first time let-7 was revealed
to regulate insulin signaling by controlling the expression of several factors
responsible for 1-cell proliferation and insulin secretion.IRS-2 and mTOR were
both found to be promoted by let-7. The study of let-7 in pancreatic 1-cells
suggests the function of insulin signaling pathways in insulin-producing cells and
provides potential targets that may contribute to therapeutic treatments of type 2
diabetes.
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